The HLA-F adjacent transcript 10 (FAT10) is a member of the ubiquitinlike gene family that alters protein function/stability through covalent ligation. Although FAT10 is induced by inflammatory mediators and implicated in immunity, the physiological functions of FAT10 are poorly defined. We report the discovery that FAT10 regulates lifespan through pleiotropic actions on metabolism and inflammation. Median and overall lifespan are increased 20% in FAT10ko mice, coincident with elevated metabolic rate, preferential use of fat as fuel, and dramatically reduced adiposity. This phenotype is associated with metabolic reprogramming of skeletal muscle (i.e., increased AMP kinase activity, β-oxidation and -uncoupling, and decreased triglyceride content). Moreover, knockout mice have reduced circulating glucose and insulin levels and enhanced insulin sensitivity in metabolic tissues, consistent with elevated IL-10 in skeletal muscle and serum. These observations suggest novel roles of FAT10 in immune metabolic regulation that impact aging and chronic disease.
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longevity | obesity | mammals T he twin selection pressures of starvation and infection have driven the evolution of proteins that coordinate nutrient homeostasis, fuel use, and immune/inflammatory responses (1-3). Signaling pathways regulated by these proteins are conserved across phyla and include insulin/IGF1, p53, Toll, peroxisome proliferator-activated receptor (PPAR), NF-κB, mitogen-activated protein kinase (MAPK), and AMP kinase (AMPK)/target of rapamycin (TOR)/forkhead box O (FOXO) pathways (1) (2) (3) (4) . Importantly, chronic dysregulation or imbalance among immune metabolic signaling networks (like in chronic overnutrition) is increasingly appreciated as an underlying cause of aging as well as chronic diseases of humans, including type 2 diabetes, atherosclerosis, inflammatory bowel disease, nonalcoholic steatohepatitis, and cancer (4, 5) .
The HLA-F adjacent transcript 10 (FAT10) gene was initially cloned as part of an effort to identify additional genes from the human MHC, and it was named according to its proximity to the HLA-F locus (6) . FAT10 is a vertebrate-specific member of the eukaryotic ubiquitin-like (UBL) protein family, containing two UBL domains arranged in tandem with a C-terminal diglycine motif (6) . Unlike the posttranslational cleavage required to expose the terminal diglycine motif of ubiquitin, the FAT10 protein is synthesized with an accessible terminal diglycine motif. FAT10 protein becomes coupled to other proteins (FAT10ylation) (7) through the action of UBL modifier activating proteins UBA6 (8, 9) and USE1 (10), which also activate ubiquitin. Both FAT10 and its conjugates are unstable and degraded by the proteasome (11, 12) . Currently, no de-FAT10ylating enzymes (analogous to deubiquitinating enzymes) have been identified, suggesting that FAT10ylation is an irreversible process.
Despite intense recent efforts to identify FAT10 substrates (10, 13, 14) , physiological role(s) of FAT10 remain obscure. FAT10 mRNA is absent or expressed at very low levels in most normal tissues but constitutively expressed during lymphocyte and dendritic cell maturation in some cell culture lines derived from B cells and several types of neoplasms (15) . Notably, FAT10 is ubiquitously induced in response to IFN-γ or TNF-α, with FAT10 mRNA being one of the most highly up-regulated transcripts in some models of inflammation (16) . FAT10 may participate in protein quality control based on the preferential binding of FAT10 to polyglutamine-modified huntingtin protein (17) and the observation of FAT10-enhanced formation of hepatocyte MalloryDenk bodies in a model of drug-induced chronic hepatitis (18, 19) .
We initially reported that young FAT10-deficient (KO) mice generated in our laboratory seemed normal in all respects but were more susceptible to LPS-induced death (20) . Because sensitivity to sepsis was shown to increase with age in mammals (21-23), we established aging colonies of KO mice and WT littermates. Surprisingly, older KO mice evinced a clear phenotype of delayed aging and extended lifespan. Complementary studies in younger mice revealed global alterations in energy and fuel metabolism, adiposity, glucose-insulin homeostasis, and inflammatory gene expression that were all consistent with delayed aging and lifespan extension. These observations identify FAT10 as a modulator of immune and metabolic homeostasis and implicate these actions in the regulation of vertebrate lifespan by FAT10.
Results
Knockout of the FAT10 Gene Prolongs Lifespan and Reduces AgeAssociated Biomarkers. Aged FAT10ko mice appeared younger than their age-and sex-matched controls, with maintenance of muscle mass (delayed sarcopenia), denser, smoother, and darker fur (Fig. S1 ), and absence of tumors. To assess impact on lifespan, we conducted Kaplan-Meier analysis (24) on mortality patterns of
Significance
For the first time we describe a physiological role for HLA-F adjacent transcript 10 (FAT10) in metabolism, obesity, and aging in mammals. We show that FAT10 knockout prevents the development of age-associated obesity in mice while extending lifespan and vigor without the appearance of deleterious developmental effects. In addition, we did not observe an increase in cancer incidence. If the role of FAT10 in humans is similar to mice, then targeting of FAT10 may hold promising therapeutic impact for the treatment of various diseases including obesity and obesity-related diseases and aging associated diseases. the two sexes compared with WT mice (Fig. 1) . The analysis showed that male and female FAT10ko mice had a 20% increase in both median and overall lifespan. Notably, 42% percent of male KOs and 52% of female KOs remained alive after the death of the last WT mouse. Wilcoxon (25) , Mantel-Haenszel (26) , and Taron-Ware (27) tests (set for a probability of 99%) generated significant P values for females (6.6 × 10 −9 , 5.99 × 10 −11 , and 6.42 × 10 , respectively) (Dataset S1 A and B). Survival among females in the middle part of the study (600-800 d) was slightly greater than among males (Wilcoxon test, P = 0.036) (Dataset S1C).
FAT10ko Mice Are Leaner than Their Control Counterparts. Increased lifespan in KO mice was associated with dramatically reduced adiposity. KO mice, independent of sex, gained significantly less weight than WT mice (Fig. S2A) . Differences in weight became more pronounced with age. Whereas WT mice gained weight through their lifespan, the preponderance of weight gain in KO mice occurred by 12 mo of age. By 3 mo of age, KO mice weighed on average 1 g less than WT mice, reflecting an ∼50% reduction in white adipose tissue (WAT) (Fig. 2 A-D) . However, there was no difference in total lean mass between genotypes (Fig. 2B) . Necropsy revealed that FAT10ko mice have reduced subcutaneous fat depots compared with WT mice (Fig. S2 B and C), with significantly less visceral periovarian adipose tissue (epididymal in males) in the KO mice compared with the WT controls. Histological examination of epididymal WAT (eWAT) revealed an ∼50% reduction in average adipocyte size (Fig. 2E) , reflecting a greater proportion of smaller adipocytes (<3,000 μm 2 ) and a coincident decrease in larger adipocytes (3,000-5,000 μm 2 ) (Fig. 2F ). There was no significant difference in epididymal adipocyte number between genotypes (KO: 3.46 ± 0.19 × 10 6 adipocytes per depot; WT: 3.75 ± 0.22 × 10 6 adipocytes per depot; n = 6, P > 0.05). Therefore, reduced adiposity in KO mice is caused by decreased adipocyte size (i.e., decreased triglyceride per cell). Consistent with smaller adipocyte size, adiponectin gene expression was greater and leptin gene expression was reduced compared with adipocytes of WT mice (Fig. 2F, Inset) . However, circulating adiponectin levels were lower than in WT (Table S1 ), reflecting overall reduction of adipose mass in the KO.
Altered Energy Expenditure and Fuel Use in FAT10ko Mice. KO mice consume more energy (per body weight) than WT mice during the night (period of active feeding) and ingest comparable levels during the day (period of sleep/intermittent feeding) (Fig. 3A) . However, FAT10ko mice expend more energy throughout 24 h than WT mice ( Fig. 3B ), despite comparable locomotor activity (Fig. 3C) . Importantly, increased energy expenditure during the day in the absence of increased energy intake result in a greater daytime negative energy balance in FAT10ko mice compared with WT mice (Fig. 3D ). Reduced adipose stores in FAT10ko mice are consistent with this greater daytime energy deficit.
Relative to WT mice, FAT10ko mice preferentially metabolize fat (as opposed to carbohydrate) for energy, resulting in a reduced respiratory quotient (RQ; RQ = CO 2 /O 2 ), even during active night feeding. This lower RQ becomes more pronounced in KO mice during the light phase, when decreased food intake results in mobilization of fat stores in WT and KO animals ( Fig. 3E ). Because fat is the exclusive fuel used for adaptive (nonshivering) thermogenesis in mice, we housed KO and WT mice at thermoneutrality (30°C) for 5 wk and measured increases in body weight and adiposity (by MRI) in response to this reduced thermogenic demand. KO mice did not gain proportionally more weight or fat than WT mice ( Fig. S3 ), indicating that greater energy expenditure in KO mice is not caused by greater demands of adaptive thermogenesis. Evidence for elevated β-oxidation in KO mice is provided at the protein level by the proportionally greater level of phosphorylated (inactive) acetyl-CoA carboxylase (ACACA) (Fig. 4B ) and decreased triglyceride content (Table S1 ). Liver triglyceride levels were comparable in WT and KO mice (Table S1 ). Overall, these data indicate that global deletion of FAT10 induces a skeletal muscle transcriptional program promoting fat oxidation. nonesterified fatty acids (NEFAs) were greater in KO compared with WT mice (Table S1 ). Second, basal and stimulated ex vivo lipolysis, indicated by glycerol release, were significantly increased in isolated KO adipocytes (Fig. 4C) . In addition, hallmarks of lipolysis were elevated in adipose tissue, including phosphorylation of the lipid droplet-associated protein perilipin [the rate-controlling event in catecholamine (fasting) -induced lipolysis] (28, 29) (Fig. 4D) , increased β-oxidation manifest as inhibitory phosphorylation of ACACA-1 (Fig. 4E) , and up-regulation of PGC1α, PPARα, ACSL1α, and UCP1 gene expression (Fig. 4F) (30, 31) . Thus, increased fatty acid release and triglyceride turnover provide a proximate physiological mechanism to explain the reduced adipocyte size and adipose mass of KO mice.
Enhanced Glucose Insulin Homeostasis in FAT10ko Mice. Leanness is associated with enhanced glucose-insulin homeostasis, which can independently promote longevity in mice (32) . KO mice maintained lower circulating glucose and insulin concentrations than WT mice (Table S1 ), resulting in significantly lower homeostatic assessment of insulin resistance values (KO: 1.93 ± 0.37; WT: 5.56 ± 0.38; P < 0.001). Improved insulin action in KO mice was confirmed at the whole-body level by more rapid glucose disposal during the i.p. insulin tolerance test (ITT). Blood glucose stabilization 1 h after insulin injection was similar in WT and KO mice (Fig. 5A) , suggesting comparable hepatic insulin clearance. KO mice were also more glucose tolerant than WT mice (Fig. 5B) , showing more efficient clearance of glucose despite lower insulin levels. During the glucose tolerance test (GTT), relative increases over baseline in first-and second-phase glucosestimulated insulin responses were comparable between KO and WT mice, indicating that reduced insulin levels in KO mice do not reflect a defect in insulin secretion. In vivo insulin signaling assays suggested that greater insulin action in KO mice reflected enhanced capacity for insulin signaling (i.e., insulin-stimulated AKT phosphorylation) in adipose, liver, and skeletal muscle.
Inflammation in Metabolic Tissues of FAT10ko Mice. FAT10 has been implicated in NF-κB-dependent inflammatory gene expression (16) , which can impair insulin signaling and promote insulin resistance in metabolic tissues (33, 34) . Consistent with enhanced insulin action and sensitivity (Figs. 4 and 5) , we observed a tissuespecific pattern of altered inflammatory gene expression in metabolic tissues of FAT10ko mice. In quadriceps, transcript levels of TNF-α and monocyte chemotactic protein-1 (MCP-1) were decreased, whereas IL-6 and IL-10 were increased (Fig. 6A) . Proinflammatory genes were generally down-regulated in eWAT of FAT10ko mice, with the exception of the induced nitric oxide synthase (iNOS) gene (Fig. S4) . Thus, although proinflammatory gene expression was generally reduced in metabolic tissues of FAT10ko mice, effects on specific NF-κB-regulated genes (e.g., IL-1β, IL-6, IL-10, iNOS, and MCP-1) varied. The most highly up-regulated transcript in our inflammatory panel was the antiinflammatory cytokine, IL-10. Moreover, IL-10 protein levels were significantly increased in both skeletal muscle and serum of KO mice (Fig. 6B) . These results suggest that deletion of FAT10 promotes an inflammation-suppressive milieu in skeletal muscle and perhaps, systemically as well.
New Aging Biomarker-FAT10 Expression Increases with Age. Aging is associated with increased expression of inflammatory cytokines in adipose tissue, concordant with impaired metabolic homeostasis. We assessed FAT10 expression in WAT obtained from young and old WT mice. FAT10 expression was evaluated compared with TNF-α expression, an established physiological biomarker of chronic inflammation in aging (35) (36) (37) (38) . QPCR analysis indicated that FAT10 mRNA expression increases with age in WAT of WT mice, comparable with the increase in TNF-α expression (Fig. 7) . These data suggest that FAT10-mediated processes are up-regulated in adipose tissue with aging and agerelated increases in inflammation. Discussion FAT10 is a pleiotropic UBL protein that has evolved with the vertebrate MHC, and it participates in protein quality control, signal transduction, and gene transcription, typically in the setting of inflammation or other cell/tissue insult (39, 40) . Apart from ubiquitin, FAT10 is the only member of the UBL family known to promote proteosomal degradation, which is required for peptide presentation by MHC-I (11). However, FAT10 modification is distinct from ubiquitination and an alternative mechanism for antigen presentation by MHC-I (41). FAT10 modification was found to be more efficient than ubiquitination in transferring proteins to the proteosome; whereas polyubiquitination of proteins is needed to enable proteosomal activity, the binding of one FAT10 molecule to its target is sufficient (42) . The induction of FAT10 expression by IFN-γ and TNF-α combined with its highly efficient role in proteosomal antigen processing may suggest that the genomic location of FAT10 within the MHC locus is the result of a coevolution process based on shared function.
Coordinate integration of nutrient sensing, energy storage, and immune/inflammatory responses has evolved under the twin selection pressures of nutrient deprivation and infection. A current paradigm of human disease pathogenesis posits that persistent dysregulation of this immunometabolic integration promotes normal aging and the development of chronic age-related disabilities, including type 2 diabetes, atherosclerosis, and cancer (2-5). Here, we identify FAT10 as a novel regulator of immune metabolic homeostasis and lifespan in healthy mice. Specifically, targeted gene deletion of FAT10 delayed the appearance of aging biomarkers and extended both median and maximum lifespan in mice. Importantly, these salutary effects on aging were coincident with global reprogramming of metabolic and inflammatory gene expression in key metabolic tissues and alterations in body composition, whole-body nutrient and energy metabolism, and glucose-insulin homeostasis that are hallmarks of delayed aging and lifespan extension.
Longevity is inversely correlated with adiposity in humans and animal models (43, 44) . FAT10ko mice had 50% less white adipose mass than WT counterparts, despite comparable energy intake. This reduction in adiposity reflected elevated rates of triglyceride hydrolysis (lipolysis) in adipocytes that were manifest as increased levels of circulating NEFAs in the fasted state and up-regulation of a counterregulatory program of fat oxidation in adipose tissues (31) . A proximate mechanism to explain increased adipocyte lipolysis in KO mice is enhanced phosphorylation of the lipid droplet protein perilipin (28, 29) . This rate-determining step in lipolysis is cAMP/protein kinase A (PKA)-dependent and tightly regulated by stimulatory actions of adrenergic signaling and glucagon as well as reciprocal inhibitory actions of insulin and adenosine on cAMP levels (45) . Future studies will be required to determine whether FAT10 regulates perilipin phosphorylation by direct interaction with components of one or more of these signaling pathways in adipocytes or indirectly by modulating adrenergic tone and/or adenosine or insulin levels.
Reduced adipose depot mass in KO mice was not associated with ectopic lipid deposition in skeletal muscle or liver, suggesting that NEFAs were being mobilized as fuel in skeletal muscle. This notion was confirmed by indirect calorimetry (i.e., reduced RQ) by a skeletal muscle gene expression signature of enhanced mitochondrial respiration, β-oxidation and uncoupling, and increased cAMP protein kinase (AMPK)-dependent phosphorylation of skeletal muscle ACACA-2 (reviewed in ref. 46) . These alterations in skeletal muscle gene expression and metabolic function are also observed in response to exercise training muscle (47) . Notably, these coordinate increases in skeletal muscle fat oxidation and uncoupling combined with AMPK activation are themselves proposed as a critical mechanism regulating the rate of aging and lifespan (uncoupling to survive) (48) . Thus, the effects of FAT10 KO on aging and lifespan are likely to reflect the combined benefits of reduced adipose mass and enhanced metabolism in skeletal muscle.
Enhanced glucose-insulin homeostasis is typically associated with reduced adiposity and itself a hallmark of lifespan extension (32) . FAT10ko mice maintained normoglycemia and showed enhanced insulin action (clearance of a glucose bolus in the GTT), despite reduced circulating insulin levels.
Enhanced insulin action in the presence of relatively low levels of insulin reflects enhanced insulin signaling [i.e., insulin-stimulated AK thymoma (AKT)/protein kinase B phosphorylation] in metabolic tissues of KO mice. How the absence of FAT10 results in improved insulin signaling is currently unclear. Our data implicate altered inflammatory gene expression-in particular, elevated IL-10 production by skeletal muscle-in the enhanced insulin sensitivity in FAT10ko mice. IL-10 suppresses inflammation and enhances tissue and whole-body insulin sensitivity by inhibiting the expression of proinflammatory cytokines and antagonizing IKK/NF-κB signaling and ER stress (28, 49) . Musclespecific transgenic overexpression of IL-10 at levels comparable with those levels measured in KO mice (present study) was shown to enhance whole-body insulin sensitivity in both lean and obese mice (50) . Up-regulation of IL-10 in skeletal muscle of KO mice may, in part, reflect the coincident modest increase in IL-6, a robust inducer of IL-10 gene expression in skeletal muscle (51) . As noted above for enhanced mitochondrial oxidative function, elevated expression of IL-10 and IL-6 are hallmarks of skeletal muscle adaptation to exercise (52) . These observations further suggest that FAT10 abrogation and its benefits on metabolic health and lifespan, in part, mimic the exercise-trained state.
Evidence presented here for important roles of FAT10 in metabolic programming and lifespan determination extends and informs recent identification of numerous FAT10 target proteins and interacting partners with acknowledged roles in energy sensing, nutrient and bile acid metabolism, and insulin-, PI3K/ Akt/mTOR-, and cAMP-dependent signaling as well as NF-κB-dependent gene expression (10, 13, 14) . Previous studies identified p53 and p62/sequestosome1 as FAT10 targets (7, 53) , and both target proteins are known to modulate energy metabolism, mitochondrial activity, adiposity, glucose-insulin homeostasis, cell stress, and aging (54, 55) . Together, these myriad and diverse functions of FAT10 substrates in metabolism and immune function support the recognition of FAT10 as a new and important node in protein networks regulating immunometabolic homeostasis. Prior in vitro studies have also suggested roles for FAT10 in mitosis (14) and chromosome abnormalities that were seen when FAT10 was overexpressed (56) . However, the normal development, relative absence of malignancies, and extended lifespan of FAT10ko mice (13) question the roles for FAT10 in these processes in vivo.
In summary, our results suggest that constitutive actions of FAT10 promote adiposity, insulin resistance, and inflammation, while attenuating fat oxidation, uncoupling, and AMPK activation in skeletal muscle. Whereas these actions may enhance survival in response to starvation or pathogen challenge, they could conceivably promote obesity and its inflammatory complications in our current environment of chronic overnutrition and sedentary lifestyle. Moreover, increases in FAT10 expression are hallmarks of chronic pathologic states, including various cancers (11, 40) , liver cirrhosis (9, 10), and HIV-associated nephropathy (57). These observations, in concert with the beneficial global effects of FAT10 abrogation on metabolic function, adiposity, inflammation, and tumorogenesis, suggest that targeting the FAT10 pathway may be an effective therapeutic approach to chronic diseases.
A number of animal models have been created that increase the lifespan of mice (58) . In one group of models, such as the FIRKO mouse (59, 60) , selective removal of a gene from a certain tissue results in increased lifespan. In a second group, animals with systemic alterations in genes, such as defects in growth hormone production or abrogation of S6 kinase (58), the animal is abnormal in either size or some other way. FAT10ko belongs to the considerably smaller group of model systems, in which complete removal of a gene prolongs lifespan without developmental deleterious effects during growth and with prolonged maintenance of vigor.
Methods
The generation of FAT10ko mice has been previously described (20) . Indirect calorimetric evaluation was performed as previously described (61) . ITTs and GTTs were performed on nonanesthetized animals, and body composition was determined by MRI as described (62) . Antibodies were purchased from Cell Signaling Technologies. Detailed information is in SI Methods.
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